Exploring future trends and their impacts
The Strategy& Insider Podcast aims to explore some of the most critical future trends and their impacts. Strategy& talks to industry experts and leading practitioners from different sectors. The conversations will make you more familiar with key developments by providing you with insights that really matter.
The first season will tackle some of the most fundamental questions in the healthcare industry.
While technology has quickly transformed how we shop, bank, and travel, it yet has to impact on how we receive healthcare. The adoption of digitally enabled tools for diagnostics, treatment, and management, for example, has been rather modest - especially compared to what is already possible. With the help of digital applications, healthcare will become more and more personalized and seamlessly integrated into everyday life. For biopharma, the future of healthcare poses both opportunities and challenges, particularly with big technology companies being at the forefront of the disruption.
Based on findings of the “Future of Health” study, Strategy& partner Thomas Solbach invited healthcare industry experts including pharma executives, leading academics and medical practitioners to discuss how the healthcare industry is expected to change.
Cancer is still one of the most common diseases worldwide, and one of the top causes of death – also because there is no known cure yet. As this makes prevention all the more crucial for patients, we spoke to renowned researcher for biomedicine and scientific author Bernd Bodenmiller about his strong passion and commitment towards better understanding cancer.
The fourteenth episode features Betül Susamis Unaran, who is the Chief Strategy and Digital Officer at Zur Rose Group. She talks about the firm’s ambition to create a new healthcare ecosystem that connects healthcare products, digital healthcare services and third-party service offerings.
The latest guest of our podcast is Aashima Gupta, Director of Global Healthcare Strategy and Solutions at Google Cloud. She shares how artificial intelligence can augment human productivity in patient care, why the future healthcare model is going to be hybrid, and why data interoperability is key for empathetic patient experiences.
This episode features Dr. Sachin Jain who is the CEO of Scan Health Plan and who used to serve in the Obama administration. Tune in to our conversation about the benefits of virtual specialty care, why we should strive for a better normal instead of a new normal and what it takes to achieve real transformation within the healthcare sector.
For the first time, we welcome two guests to our podcast: Henrik Matthies and Julia Hagen from the Health Innovation Hub (hih) share their insights straight out of the ,digital forge' of Germany's Federal Ministry of Health. They stress the importance of an ecosystem approach and explain how COVID-19 may have a silver lining for the digitization of healthcare.
The tenth episode revolves around the digitization of mental healthcare. Our guest Nora Blum – founder and CEO of the German start-up Selfapy – illustrates that digital apps are a decisive tool in the treatment of mental diseases and increasingly help patients with depressions, eating disorders and other psychiatric illnesses to receive faster and more flexible medical care.
The ninth episode brings you ever closer to the future of healthcare with Thomas discussing the possibilities of digital biomarkers for modern medicine with Dan Vahdat, founder and CEO of Huma. Together, they shed light on the prospect of diagnosing diseases in the earliest stages and how this contributes to a more preventative and personalized care for patients.
While COVID-19 makes it necessary for the healthcare system to increase the use of digital means at the moment, this could also function as a digital catalyst and create sustainable change. Dr. Johannes Wimmer, Germany's leading TV doctor, explains why this would be a positive outcome of the crisis in the podcast's eighth episode.
Together with Prof. Dr. Christiane Woopen, medical ethicist and Executive Director of ceres at the University of Cologne, Thomas discusses the implications of COVID-19 for basic human rights and that health is only one of our fundamental goods, whereas freedom is the highest good from an ethical perspective.
Peter Albiez, Chairman of the Management Board of Pfizer Germany, is our latest podcast guest with whom Thomas talked about his vision for healthcare to reward health rather than sickness. Listen now to learn what other opportunities health and life sciences offer to future competitiveness and progress.
The guest of our fifth episode is Dr. Hamed Al Hashemi, Director for Strategy, Performance and Risk at the Department of Health in Abu Dhabi. Find out how the emirate plans to integrate new means of technology into its healthcare system.
In the fourth episode, Thomas welcomes Dr. Georg Matheis, cardiac surgeon and one of Germany’s pioneering founders in healthcare. They discuss how to regain the patient-physician relationship, megatrends in surgery, and the current situation of healthcare in Europe.
In the third episode, Teresa Graham, Head of Global Product Strategy at Roche Pharma, discusses the role big tech companies will play and how technology will change how patients access medicine in the future.
In the second episode of the Future of Health podcast series, Thomas discusses the changes data-driven biomedicine will bring to the healthcare sector with Dr. Torsten Schwede, Vice President for Research and professor for bioinformatics at University of Basel.
In the first episode, Thomas meets with Chief Oncologist at Universitätsspital Baselland, Dr. Andreas Wicki. Tune in to learn about how data analytics will help medicine move from curing diseases to preventing them and who will win the race around steering the future of health.
Welcome to the Strategy& Insider Podcast. In our first season, we will discuss some of the most fundamental questions about the Future of Health. Our guests are experts across all sectors of the healthcare industry including pharma executives, leading academics and medical physicians.